Ubs Group Ag Galecto, Inc. Transaction History

Ubs Group Ag

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	SELL	$0.52 - $0.78 $1,460 - $2,190	-2,808 Reduced 39.62%	4,280 $3,000
Q3 2023 Nov 09, 2023	BUY	$0.56 - $3.17 $3,969 - $22,468	7,088 New	7,088 $5,000
Q1 2023 May 12, 2023	BUY	$1.21 - $2.86 $3,005 - $7,104	2,484 New	2,484 $4,000
Q3 2022 Nov 10, 2022	BUY	$1.59 - $60.0 $6,514 - $245,820	4,097 New	4,097 $8,000
Q2 2022 Aug 10, 2022	SELL	$1.22 - $2.74 $3,043 - $6,836	-2,495 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$1.72 - $3.31 $7,306 - $14,060	-4,248 Reduced 63.0%	2,495 $5,000
Q4 2021 Feb 14, 2022	BUY	$2.3 - $3.58 $15,508 - $24,139	6,743 New	6,743 $20,000
Q3 2021 Nov 15, 2021	SELL	$3.59 - $5.0 $28,080 - $39,110	-7,822 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$4.63 - $8.0 $36,215 - $62,576	7,822 New	7,822 $40,000

21.2K

Ticker GLTO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,395,700
Market Cap $131M
Description
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.